Menu
← Oncology Approval Tracker
FDA DECISION ·
Sarclisa + VRd
isatuximab-irfc with bortezomib, lenalidomide and dexamethasone · Sanofi
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with newly diagnosed multiple myeloma ineligible for autologous stem cell transplant; use with bortezomib, lenalidomide and dexamethasone.
LAMPGEN ANALYSIS
Why it matters
The anti-CD38 antibody joins a frontline triplet for transplant-ineligible patients, distinct from transplant-eligible induction regimens.
What research teams should watch
Document transplant eligibility and prearrange blood-bank communication because anti-CD38 therapy can interfere with compatibility testing.
PRIMARY RECORDS